Complete Radiologic Response After 177Lu-DOTATATE Therapy in Treatment of a Lung Metastatic Intracranial Atypical Meningioma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40739709.
- Also identified by DOI 10.1097/RLU.0000000000005750.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Meningiomas are usually benign solitary intracranial tumors. In rare cases, atypical [World Health Organization (WHO) grade II) and anaplastic (WHO grade III) meningiomas can lead to distant metastases. Meningioma cells express somatostatin receptor subtype 2, providing a rationale for peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs in patients with aggressive meningiomas. A 68-year-old woman treated surgically in 2013 for a grade II cerebral meningioma presented 6 years later with pulmonary relapse. Complete response was achieved after 4 cycles of 177Lu-DOTATATE PRRT, without recurrence after 3 years of follow-up.
Medical subject headings
- Meningioma
- Octreotide
- Lung Neoplasms
- Organometallic Compounds
- Meningeal Neoplasms